Until recently, FDA-approved treatments for Alzheimer’s disease (AD) were limited to modestly effective symptomatic agents (e.g., donepezil, memantine), but in 2021, Biogen / Eisai’s Aduhelm (aducanumab) became the first potential disease-modifying therapy (DMT) approved for AD—an event marked by considerable controversy. Other DMTs (e.g., from Eisai / Biogen, Eli Lilly, Roche, Novo Nordisk) and symptomatic agents for treating AD-associated psychosis (Acadia’s Nuplazid) and agitation (Lundbeck / Otsuka’s Rexulti, Avanir / Otsuka’s AVP-786, Axsome’s AXS-05) are advancing through late-phase development with near-term launch potential; their approval could meaningfully alter the dynamics of this market, driven by clear need, strong market demand, and premium pricing—but only if these treatments are accessible. As the AD therapy market enters a new era, understanding neurologists’ preferences for and expectations from new therapeutics, counterpoised by payers’ receptivity to high-priced brands entering a highly underserved but heavily generic market, will be key for pharmaceutical companies developing new drugs or considering entering this wide-open arena.
U.S. Access & Reimbursement provides integrated brand- and disease-level insight on reimbursement dynamics and the impact of U.S. payer policy on physician prescribing behavior in the market access environment, including up-to-date analysis of drug coverage and restriction policies and payer and prescriber perspectives on key marketed drugs and receptivity to emerging therapies.
Markets covered: United States
Key drugs: AChEIs, memantine, Adlarity, Namzaric, Nuplazid, Rexulti, Aduhelm, lecanemab, donanemab, gantenerumab, semaglutide, AVP-786, AXS-05.
Key companies: Biogen, Eisai, Novartis, Novo Nordisk, AbbVie, Corium, Eli Lilly, Roche, Johnson & Johnson, Lundbeck / Otsuka, Acadia Pharmaceuticals.